Literature DB >> 22306850

Ambulatory blood pressure monitoring and development of cardiovascular events in high-risk patients included in the Spanish ABPM registry: the CARDIORISC Event study.

Alejandro de la Sierra1, José R Banegas, Julián Segura, Manuel Gorostidi, Luis M Ruilope.   

Abstract

BACKGROUND AND AIM: Ambulatory blood pressure monitoring (ABPM) is superior to conventional BP measurement in predicting outcome, with baseline 24-h, daytime and night-time absolute values, as well as relative nocturnal decline, as powerful determinants of prognosis. We aimed to evaluate ABPM estimates on the appearance of cardiovascular events and mortality in a cohort of high-risk treated hypertensive patients. METHODS AND
RESULTS: A total of 2115 treated hypertensive patients with high or very high added risk were evaluated by means of office and 24-h ABPM. Cardiovascular events and mortality were assessed after a median follow-up of 4 years. Two hundred and sixty-eight patients (12.7%) experienced a primary event (nonfatal coronary or cerebrovascular event, heart failure hospitalization or cardiovascular death) and 114 died (45 from cardiovascular causes). In a multiple Cox regression model, and after adjusting for baseline cardiovascular risk and office BP, night-time SBP predicted cardiovascular events [hazard ratio for each SD increase: 1.45; 95% confidence interval (CI) 1.29-1.59]. Values above 130 mmHg increased the risk by 52% in comparison to values less than 115 mmHg.
CONCLUSION: In addition to clinical determinants of cardiovascular risk and conventional BP, ABPM performed during treatment adds prognostic significance on the development of cardiovascular events in high-risk hypertensive patients. Among different ABPM-derived values, night-time SBP is the most potent predictor of outcome.

Entities:  

Mesh:

Year:  2012        PMID: 22306850     DOI: 10.1097/HJH.0b013e328350bb40

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  18 in total

Review 1.  Ambulatory Blood Pressure Monitoring in the Diagnosis, Prognosis, and Management of Resistant Hypertension: Still a Matter of our Resistance?

Authors:  Antonios A Lazaridis; Pantelis A Sarafidis; Luis M Ruilope
Journal:  Curr Hypertens Rep       Date:  2015-10       Impact factor: 5.369

2.  Desoxycorticosterone pivalate-salt treatment leads to non-dipping hypertension in Per1 knockout mice.

Authors:  K Solocinski; M Holzworth; X Wen; K-Y Cheng; I J Lynch; B D Cain; C S Wingo; M L Gumz
Journal:  Acta Physiol (Oxf)       Date:  2016-10-03       Impact factor: 6.311

Review 3.  Azilsartan medoxomil: a review of its use in hypertension.

Authors:  Caroline M Perry
Journal:  Clin Drug Investig       Date:  2012-09-01       Impact factor: 2.859

Review 4.  Prevalence of white-coat and masked hypertension in national and international registries.

Authors:  Manuel Gorostidi; Ernest Vinyoles; José R Banegas; Alejandro de la Sierra
Journal:  Hypertens Res       Date:  2014-10-16       Impact factor: 3.872

5.  Determinants of concentric left ventricular hypertrophy in patients with resistant hypertension: RESIST-POL study.

Authors:  Piotr Dobrowolski; Aleksander Prejbisz; Anna Klisiewicz; Elżbieta Florczak; Justyna Rybicka; Andrzej Januszewicz; Piotr Hoffman
Journal:  Hypertens Res       Date:  2015-03-19       Impact factor: 3.872

6.  Variations in 24-Hour BP Profiles in Cohorts of Patients with Kidney Disease around the World: The I-DARE Study.

Authors:  Paul E Drawz; Roland Brown; Luca De Nicola; Naohiko Fujii; Francis B Gabbai; Jennifer Gassman; Jiang He; Satoshi Iimuro; James Lash; Roberto Minutolo; Robert A Phillips; Kyle Rudser; Luis Ruilope; Susan Steigerwalt; Raymond R Townsend; Dawei Xie; Mahboob Rahman
Journal:  Clin J Am Soc Nephrol       Date:  2018-07-05       Impact factor: 8.237

Review 7.  Integrating Out-of-Office Blood Pressure in the Diagnosis and Management of Hypertension.

Authors:  Jordana B Cohen; Debbie L Cohen
Journal:  Curr Cardiol Rep       Date:  2016-11       Impact factor: 2.931

8.  Prevalence of office and ambulatory hypotension in treated hypertensive patients with coronary disease.

Authors:  Juan A Divisón-Garrote; Juan J de la Cruz; Alejandro de la Sierra; Ernest Vinyoles; Manuel Gorostidi; Carlos Escobar-Cervantes; Julián Segura; Vivencio Barrios; Luis M Ruilope; José R Banegas
Journal:  Hypertens Res       Date:  2020-05-12       Impact factor: 3.872

9.  Impact of disease duration and cardiovascular dysautonomia on hypertension in Parkinson's disease.

Authors:  Davide L Vetrano; Maria S Pisciotta; Vincenzo Brandi; Maria R Lo Monaco; Alice Laudisio; Graziano Onder; Domenico Fusco; Paolo D L'Angiocola; Anna R Bentivoglio; Roberto Bernabei; Giuseppe Zuccalà
Journal:  J Clin Hypertens (Greenwich)       Date:  2016-11-02       Impact factor: 3.738

10.  Effect of Olmesartan-Based Therapies on Therapeutic Indicators Obtained Through Out-of-Office Blood Pressure.

Authors:  Manuel Gorostidi
Journal:  Cardiol Ther       Date:  2015-06-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.